Extracellular matrix remodeling in atrial fibrosis: Mechanisms and implications in atrial fibrillation

Weber, 1991, Pathological hypertrophy and cardiac interstitium. Fibrosis and renin–angiotensin–aldosterone system, Circulation, 83, 1849, 10.1161/01.CIR.83.6.1849 Mazzini, 2008, Pharmacotherapy for atrial arrhythmias: present and future, Heart Rhythm, 5, S26, 10.1016/j.hrthm.2008.01.023 Callans, 2008, Apples and oranges: comparing antiarrhythmic drugs and catheter ablation for treatment of atrial fibrillation, Circulation, 118, 2488, 10.1161/CIRCULATIONAHA.108.823179 Bajpai, 2008, Treatment of atrial fibrillation, Br. Med. Bull., 88, 75, 10.1093/bmb/ldn046 Kagitani, 2004, Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats, J. Hypertens., 22, 1007, 10.1097/00004872-200405000-00024 Brilla, 1993, Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism, J. Mol. Cell. Cardiol., 25, 563, 10.1006/jmcc.1993.1066 Brilla, 1990, Remodeling of the rat right and left ventricles in experimental hypertension, Circ. Res., 67, 1355, 10.1161/01.RES.67.6.1355 Yang, 2008, Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs, Chin. Med. J. (Engl), 121, 38, 10.1097/00029330-200801010-00008 Robert, 1999, Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis, Hypertension, 33, 981, 10.1161/01.HYP.33.4.981 Johar, 2006, Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase, FASEB J., 20, 1546, 10.1096/fj.05-4642fje Thiedemann, 1977, Left atrial ultrastructure in mitral valvular disease, Am. J. Pathol., 89, 575 Frustaci, 1997, Histological substrate of atrial biopsies in patients with lone atrial fibrillation, Circulation, 96, 1180, 10.1161/01.CIR.96.4.1180 Remes, 2008, Persistent atrial fibrillation in a goat model of chronic left atrial overload, J. Thorac. Cardiovasc. Surg., 136, 1005, 10.1016/j.jtcvs.2008.05.015 Verheule, 2004, Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1, Circ. Res., 94, 1458, 10.1161/01.RES.0000129579.59664.9d Sanfilippo, 1990, Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study, Circulation, 82, 792, 10.1161/01.CIR.82.3.792 Verheule, 2003, Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation, Circulation, 107, 2615, 10.1161/01.CIR.0000066915.15187.51 Knackstedt, 2008, Association of echocardiographic atrial size and atrial fibrosis in a sequential model of congestive heart failure and atrial fibrillation, Cardiovasc. Pathol., 17, 318, 10.1016/j.carpath.2007.12.003 Van Wagoner, 2003, Electrophysiological remodeling in human atrial fibrillation, Pacing Clin. Electrophysiol., 26, 1572, 10.1046/j.1460-9592.2003.t01-1-00234.x Wijffels, 1995, Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats, Circulation, 92, 1954, 10.1161/01.CIR.92.7.1954 Dhein, 2006, Role of connexins in atrial fibrillation, Adv. Cardiol., 42, 161, 10.1159/000092568 Luo, 2007, Fibrosis of collagen I and remodeling of connexin 43 in atrial myocardium of patients with atrial fibrillation, Cardiology, 107, 248, 10.1159/000095501 Dhein, 2002, Pharmacological modulation and differential regulation of the cardiac gap junction proteins connexin 43 and connexin 40, Biol. Cell, 94, 409, 10.1016/S0248-4900(02)00018-7 Cha, 2004, Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure, Circulation, 109, 412, 10.1161/01.CIR.0000109501.47603.0C Tsai, 2008, Molecular genetics of atrial fibrillation, J. Am. Coll. Cardiol., 52, 241, 10.1016/j.jacc.2008.02.072 Schotten, 2004, Loss of atrial contractility is primary cause of atrial dilatation during first days of atrial fibrillation, Am. J. Physiol., Heart Circ. Physiol., 287, H2324, 10.1152/ajpheart.00581.2004 Li, 2005, Endothelin-1-induced arrhythmogenic Ca2+ signaling is abolished in atrial myocytes of inositol-1,4,5-trisphosphate(IP3)-receptor type 2-deficient mice, Circ. Res., 96, 1274, 10.1161/01.RES.0000172556.05576.4c Eckstein, 2008, Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria, Prog. Biophys. Mol. Biol., 97, 435, 10.1016/j.pbiomolbio.2008.02.019 Young, 2008, Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation, Curr. Opin. Nephrol. Hypertens., 17, 174, 10.1097/MNH.0b013e3282f56854 Brilla, 1992, Mineralocorticoid excess, dietary sodium, and myocardial fibrosis, J. Lab. Clin. Med., 120, 893 Sun, 1997, Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion, Cardiovasc. Res., 35, 138, 10.1016/S0008-6363(97)00097-7 Schmidt, 2003, Aldosterone-induced cardiac damage: focus on blood pressure independent effects, Am. J. Hypertens., 16, 80, 10.1016/S0895-7061(02)03199-0 Silvestre, 1998, Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation, J. Biol. Chem., 273, 4883, 10.1074/jbc.273.9.4883 Rocha, 2000, Aldosterone: a mediator of myocardial necrosis and renal arteriopathy, Endocrinology, 141, 3871, 10.1210/en.141.10.3871 Hood, 1960, Studies on the metabolic effects of spironolactone in man, Ann. N.Y. Acad. Sci., 88, 864, 10.1111/j.1749-6632.1960.tb20077.x Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N. Engl. J. Med., 341, 709, 10.1056/NEJM199909023411001 Zannad, 2000, Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Rales Investigators, Circulation, 102, 2700, 10.1161/01.CIR.102.22.2700 Shehab, 2008, A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure, Cardiovasc. J. Afr., 19, 292 Milliez, 2005, Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction, Eur. Heart J., 26, 2193, 10.1093/eurheartj/ehi478 Bunda, 2009, Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase/Akt, J. Biol. Chem., 284, 16633, 10.1074/jbc.M109.008748 Nishioka, 2007, Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation, J. Cardiovasc. Pharmacol., 49, 261, 10.1097/FJC.0b013e318033dfd4 Barnes, 2005, Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure, Ann. Pharmacother., 39, 68, 10.1345/aph.1E306 Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N. Engl. J. Med., 348, 1309, 10.1056/NEJMoa030207 Akashiba, 2008, Valsartan improves l-NAME-exacerbated cardiac fibrosis with TGF-beta inhibition and apoptosis induction in spontaneously hypertensive rats, J. Cardiol., 52, 239, 10.1016/j.jjcc.2008.07.018 Kumagai, 2003, Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation, J. Am. Coll. Cardiol., 41, 2197, 10.1016/S0735-1097(03)00464-9 Disertori, 2009, Valsartan for prevention of recurrent atrial fibrillation, N. Engl. J. Med., 360, 1606, 10.1056/NEJMoa0805710 Zhao, 2008, Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats, Mol. Cell. Biochem., 317, 43, 10.1007/s11010-008-9803-8 Shimano, 2008, Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure, Heart Rhythm, 5, 451, 10.1016/j.hrthm.2007.12.010 Xiao, 2004, Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death, Am. J. Pathol., 165, 1019, 10.1016/S0002-9440(10)63363-9 Nakajima, 2000, Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart, Circ. Res., 86, 571, 10.1161/01.RES.86.5.571 Paradis, 2000, Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling, Proc. Natl. Acad. Sci. U. S. A., 97, 931, 10.1073/pnas.97.2.931 Bauer, 1997, Myocardial angiotensin receptor type 1 gene expression in a rat model of cardiac volume overload, Basic Res. Cardiol., 92, 139, 10.1007/BF00788631 Burstein, 2008, Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences, Circulation, 117, 1630, 10.1161/CIRCULATIONAHA.107.748053 de Gasparo, 2000, International union of pharmacology. XXIII. The angiotensin II receptors, Pharmacol. Rev., 52, 415 Lymperopoulos, 2009, An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo, Proc. Natl. Acad. Sci. U. S. A., 106, 5825, 10.1073/pnas.0811706106 Kassiri, 2005, Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors, Thromb. Haemost., 93, 212, 10.1160/TH04-08-0522 Herpel, 2006, Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy, Histopathology, 48, 736, 10.1111/j.1365-2559.2006.02398.x Cardin, 2007, Contrasting gene expression profiles in two canine models of atrial fibrillation, Circ. Res., 100, 425, 10.1161/01.RES.0000258428.09589.1a Bouzeghrane, 2005, Enhanced expression of fibrillin-1, a constituent of the myocardial extracellular matrix in fibrosis, Am. J. Physiol., Heart Circ. Physiol., 289, H982, 10.1152/ajpheart.00151.2005 Lin, 2007, Increased expression of extracellular matrix proteins in rapid atrial pacing-induced atrial fibrillation, Heart Rhythm, 4, 938, 10.1016/j.hrthm.2007.03.034 Ramirez, 2009, Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling, Curr. Opin. Cell Biol., 10.1016/j.ceb.2009.05.005 Spinale, 2007, Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function, Physiol. Rev., 87, 1285, 10.1152/physrev.00012.2007 Mukherjee, 2006, Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation, Am. J. Cardiol., 97, 532, 10.1016/j.amjcard.2005.08.073 Moe, 2008, Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure, J. Card. Fail., 14, 768, 10.1016/j.cardfail.2008.07.229 Baudino, 2008, Cell patterning: interaction of cardiac myocytes and fibroblasts in three-dimensional culture, Microsc. Microanal., 14, 117, 10.1017/S1431927608080021 Hirose, 2009, Diacylglycerol kinase zeta inhibits G(alpha)q-induced atrial remodeling in transgenic mice, Heart Rhythm, 6, 78, 10.1016/j.hrthm.2008.10.018 Zaman, 2009, A profibrotic effect of plasminogen activator inhibitor type-1 (PAI-1) in the heart, Exp. Biol. Med. (Maywood), 234, 246, 10.3181/0811-RM-321 Duisters, 2009, miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling, Circ. Res., 104, 170, 10.1161/CIRCRESAHA.108.182535 Recchia, 2009, Endothelin-1 induces connective tissue growth factor expression in cardiomyocytes, J. Mol. Cell. Cardiol., 46, 352, 10.1016/j.yjmcc.2008.11.017